Introduction
That medicaments can be absorbed through the skin has been known for a long time. While this route is usually of little significance percutaneous absorption of potent compounds can be important. The application of corticosteroid ointments and creams only permits an approximate dosage per unit area. An alternative approach is to use a range of steroid preparations of differing potency, so that an appropriate strength may be selected, depending on the diagnosis or severity of the disease.
The prolonged application of any potent corticosteroid may lead to atrophic skin changes and there is a risk of at least transient suppression ofhypothalamic-pituitary-adrenal (H.P.A.) function. Thus, a corticosteroid with greater topical antiinflammatory activity than hydrocortisone but lesser potential for inducing side effects than the more potent compounds is needed. We describe here studies performed with a new glucocorticoid-clobetasone butyrate-to investigate its antiinflammatory activity and effect on H.P.A. function in patients with skin diseases. The use of an animal model to assess atrophic potential is also described. 
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Cream normal in the other three. The urinary oxogenic steroid levels, though a little reduced during treatment in four patients, were not significantly different from pretreatment values. The pretreatment I.S.T. and S.T.T. results were normal. The results (I.S.T.) after treatment were abnormal in three cases, though only marginally so in two of them.
The second group comprised three patients treated with clobetasone butyrate 0-05°/ ointment (Molivate). Two patients had atopic eczema affecting 10000 and 900% of body surface, and the third had constitutional eczema covering 6000. All pretreatment and posttreatment I.S.T. and S.T.T. results were normal. The third patient showed no variation in daily plasma corticosteroid levels during active treatment.
In the patient affected over 90% of his body surface the plasma and urinary corticosteroids remained within normal limits though there were minimal falls of both levels in the middle of treatment ( fig. 3 ). The remaining patient had similar mid-treatment falls but to a greater degree. In both these patients the levels recovered while treatment continued. All three patients responded to treatment and their skin was free of rash by the end of the study. Healing was slower than might have been expected with more potent corticosteroids. 
EFFECT ON EPIDERMIS
A method of inducing epidermal thinning in pigs by the application of corticosteroids has been described by Winter and Wilson. 5 The formulated steroidal compounds were applied to the shaved dorsal skin of the large white domestic pig. Standard quantities packed in coded identical tubes were spread under occlusive dressings on five days of each week for seven weeks. Unmedicated ointment or cream base and hydrocortisone 100 were used as controls. Biopsies were performed before and throughout treatment. Before the code was broken the relative effect of various corticosteroids on epidermal thickness was judged qualitatively by histological appearance and quantitatively by projecting an image of a cross-section on paper and measuring the area of the epidermis with a planimeter.
Clobetasone butyrate 0 0500 was compared in this test with five other topically active corticosteroid ointments. The six fell into three groups: those with a pronounced effect-flurandrenolone 0-05% and fluocinolone acetonide 0 0250o; those with a slight to moderate effect-triamcinolone acetonide 0-10, flurandrenolone 0.0125%, and clobetasone butyrate 0-0500; and those with little or no effectunmedicated base and hydrocortisone 100. Clobetasone butyrate ointment caused the least epidermal thinning among the slight-tomoderate group. The detailed results of this study are described The tests of the effect of percutaneously absorbed clobetasone butyrate on H.P.A. function were carried out under conditions which predisposed to maximum absorption-namely, extensive disruption of the cutaneous barrier, the application of large quantities of ointment, and hydration of the skin by virtually continuous whole-body occlusion. The minimal effect observed was in definite contrast to that seen with other preparations. Betamethasone valerate caused H.P.A. axis suppression in all patients tested,4 and, though in one or two the corticosteroid levels showed a tendency to rise again during treatment as the skin healed, full recovery was not seen until after treatment had ceased. In a similar study patients treated with clobetasol propionate remained suppressed throughout the period of active treatment (D. D. Munro, unpublished data), and there is evidence that this potent compound can cause H.P. A.suppression in ordinary clinical use, especially when the amount applied to the skin is excessive.7 8 This principle applies to all potent corticosteroid ointments whether or not they contain halogen atoms. In a further similar study of four patients using hydrocortisone butyrate cream 0-1%-a preparation claimed to be "as safe as hydrocortisone"-comparison of 50 plasma cortisol levels during treatment with 15 pretreatment and 11 posttreatment readings showed suppression of plasma cortisol (P <0-001 and P <0 05, respectively, for pretreatment v. during treatment and during treatment v. posttreatment). In contrast, three of the six patients on whom clobetasone butyrate 0-1% was used shawed no suppression. Clinically obvious atrophy induced by topical corticosteroids involves dermal as well as epidermal changes. In the pig dermal changes are difficult to quantify. Corticosteroids which eventually cause dermal thinning may reasonably be assumed first to cause changes in the epidermis. A lesser effect on the outer structures probably indicates that there would be a delay in the appearance of changes in the dermis.
As with an effect on pituitary adrenal function, so an effect on collagen seems to be inseparable from glucocorticoid antiinflammatory activity. Though hydrocortisone has not been shown to cause thinning of the skin in the pig, and atrophy after its topical use is not seen in patients, the high circulating cortisol levels found in Cushing's syndrome are associated with atrophic skin changes.
Conclusions.-Clobetasone butyrate 0-05% is a new corticosteroid with topical anti-inflammatory activity greater than hydrocortisone 1% and fluocortolone 02%. Under the most stringent conditions its effect on H.P.A. function was minimal and in an animal model it caused less epidermal thinning than the other steroids tested, with the exception only of,hydrocortisone. Such a combination of clinical activity with a wide margin of safety should make clobetasone butyrate a useful preparation for the management of the more tractable inflammatory dermatoses or where a high ratio of safety to efficacy is required. It also provides the means of a more logical approach to the management of chronic conditions by enabling courses of the more potent corticosteroids necessary to control severe exacerbations to be alternated with maintenance treatment that is less likely to give rise to problems.
